Adiponectin: an attractive marker for metabolic disorders in Chronic Obstructive Pulmonary Disease (COPD).

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease which may be complicated by development of co-morbidities including metabolic disorders. Metabolic disorders commonly associated with this disease contribute to lung function impairment and mortality. Systemic inflammation appears to be a major factor linking COPD to metabolic alterations. Adipose tissue seems to interfere with systemic inflammation in COPD patients by producing a large number of proteins, known as "adipokines", involved in various processes such as metabolism, immunity and inflammation. There is evidence that adiponectin is an important modulator of inflammatory processes implicated in airway pathophysiology. Increased serum levels of adiponectin and expression of its receptors on lung tissues of COPD patients have recently highlighted the importance of the adiponectin pathway in this disease. Further, in vitro studies have demonstrated an anti-inflammatory activity for this adipokine at the level of lung epithelium. This review focuses on mechanisms by which adiponectin is implicated in linking COPD with metabolic disorders.

• Authors: Andrea Bianco, Gennaro Mazzarella, Viviana Turchiarelli, Ersilia Nigro, Graziamaria Corbi, Olga Scudiero, Matteo Sofia, Aurora Daniele
• Journal: Nutrients (Nutrients) Vol. 5 Issue 10 Pg. 4115-25 (Oct 14 2013) ISSN: 2072-6643 [Electronic] Switzerland
• PMID: 24128974 (Publication Type: Journal Article, Review)

Chemical References

• Adiponectin
• Biomarkers

Topics

• Adiponectin (blood)
• Adipose Tissue (metabolism)
• Animals
• Biomarkers (blood)
• Comorbidity
• Disease Models, Animal
• Humans
• Inflammation (physiopathology)
• Metabolic Diseases (blood, diagnosis, epidemiology)
• Pulmonary Disease, Chronic Obstructive (blood, diagnosis, epidemiology)